A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
| Condition | Multiple Myeloma |
|---|---|
| Phase | Phase 3 |
| Sponsor | Janssen Research & Development, LLC |
| Status | Active, not recruiting |
| Enrollment | 419 participants |
| Interventions | Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab |
| Start date | Jun 12, 2020 |
| Completion date | May 1, 2024 |
| Results posted | May 20, 2025 |
Summary
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
Progression Free Survival (PFS)
| Arm A: Standard Therapy: PVd or DPd | 11.79 months |
|---|---|
| Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | NA months |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myel — M.D. Anderson Cancer Center